Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 41, pages 377–383 (2008)Cite this article

Abstract

Although thymoglobulin and alemtuzumab are frequently used in hematopoietic stem cell transplantation (HSCT), little is known of their effects on NK cells, which mediate important functions in post-transplantation immunology. In the present study, we determined NK cell death in vitro using propidium iodide and Annexin V. The NK cell activity in 34 patients at day +30 after allogeneic HSCT was assessed using the CD107a assay. Alemtuzumab and thymoglobulin were similarly very potent in inducing NK cell death in vitro. Even in low concentrations (<1 μg/ml) the antibodies induced apoptosis and necrosis in a relevant percentage of NK cells (>30%). However, the number of tumor reactive (CD107a+) NK cells was 13.16 per μl and 1.15 per μl (mean) in patients receiving T-cell depletion with 6 mg/kg thymoglobulin and in patients receiving 100 mg alemtuzumab, respectively (P=0.02). Although thymoglobulin and alemtuzumab are equally NK cell toxic in vitro, the recovery of NK cell frequency and anti-tumor reactivity is reduced in recipients of alemtuzumab. Our findings can be explained by a longer half-life of alemtuzumab as compared to active thymoglobulin under therapeutic conditions. Prolonged immunosuppression with increased risk of infections and tumor relapse are a potential threat to patients undergoing HCST and receiving alemtuzumab as T-cell depletion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Ferrara JL, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.

    Article  CAS  PubMed  Google Scholar 

  2. Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631–643.

    Article  PubMed  Google Scholar 

  3. Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005; 33: 920–927.

    Article  CAS  PubMed  Google Scholar 

  4. Fehse N, Fehse B, Kroger N, Zabelina T, Freiberger P, Kruger W et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 2003; 12: 237–242.

    Article  PubMed  Google Scholar 

  5. Giebel S, Dziaczkowska J, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Kruzel T et al. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic haematopoietic cell transplantation. Ann Transplant 2005; 10: 29–33.

    PubMed  Google Scholar 

  6. Appelbaum FR . Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385–389.

    Article  CAS  PubMed  Google Scholar 

  7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  PubMed  Google Scholar 

  8. Alter G, Malenfant JM, Altfeld M . CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15–22.

    Article  CAS  PubMed  Google Scholar 

  9. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005; 19: 835–840.

    Article  CAS  PubMed  Google Scholar 

  10. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415–1420.

    CAS  PubMed  Google Scholar 

  11. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C . A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39–51.

    Article  CAS  PubMed  Google Scholar 

  12. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713–733.

    CAS  PubMed  Google Scholar 

  13. Lozzio BB, Lozzio CB . Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res 1979; 3: 363–370.

    Article  CAS  PubMed  Google Scholar 

  14. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814–819.

    Article  CAS  PubMed  Google Scholar 

  15. Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.

    Article  CAS  PubMed  Google Scholar 

  16. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G . Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261–267.

    Article  CAS  PubMed  Google Scholar 

  17. Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003; 9: 460–471.

    Article  CAS  PubMed  Google Scholar 

  18. Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204–212.

    Article  CAS  PubMed  Google Scholar 

  19. Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051–1059.

    Article  CAS  PubMed  Google Scholar 

  20. Charbonnier A, Sainty D, Faucher C, Arnoulet C, Chabannon C, Blaise D . Immune reconstitution after blood cell transplantation. Hematol Cell Ther 1997; 39: 261–264.

    Article  CAS  PubMed  Google Scholar 

  21. Lowdell MW, Craston R, Ray N, Koh M, Galatowicz G, Prentice HG . The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant 1998; 21: 679–686.

    Article  CAS  PubMed  Google Scholar 

  22. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H . Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology, and Transfusion Medicine, Berlin, Charité, Germany

    O Penack, L Fischer, C Gentilini, A Nogai, A Muessig, K Rieger, S Ganepola, E Thiel & L Uharek

  2. Department of Biostatistics and Clinical Epidemiology, Berlin, Charité, Germany

    A Stroux

  3. Department of Internal Medicine III, Hematology and Oncology, Johannes Gutenberg-University of Mainz, Mainz, Germany

    W Herr & R G Meyer

Authors
  1. O Penack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Stroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Gentilini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Nogai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Muessig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Rieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Ganepola
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R G Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L Uharek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Penack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penack, O., Fischer, L., Stroux, A. et al. Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplant 41, 377–383 (2008). https://doi.org/10.1038/sj.bmt.1705911

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705911

Keywords

Search

Advanced search

Quick links